Analyst Price Targets — IBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 8, 2026 10:30 am | — | Raymond James | $5.00 | $1.82 | TheFly | iBio initiated with an Outperform at Raymond James |
| October 17, 2025 10:19 am | Roanna Ruiz | Leerink Partners | $2.00 | $0.85 | TheFly | iBio initiated with an Outperform at Leerink |
| July 22, 2024 8:30 am | Kemp Dolliver | Loop Capital Markets | $3.60 | $2.21 | StreetInsider | Brookline Capital Markets Starts iBio, Inc. (IBIO) at Buy |
Latest News for IBIO
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference and the…
IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition
Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) of its bispecific antibody Reported new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, with visceral fat reduced by 6.7% and total fat mass by…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IBIO.
U.S. House Trading
No House trades found for IBIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.